Abstract 32P
Background
Hypoxia is characterized by low oxygen levels in tissues and plays a significant role in the development and progression of gliomas. Hypoxia induces activation of several signals including STAT3 which has been implicated in the cancer progression and development of drug resistance including in gliomas used temozolomide (TMZ) via modulation of O6-methylguanin-DNA-methyltransferase (MGMT) mediated repair of TMZ-induced DNA damage.
Methods
Our study was focused on the expression of STAT3 and hypoxia related factors in a set of repeatedly resected glioma patients (one patient without treatment, seven patients with chemoradiotherapy) and glioma cell lines with normal and knockout STAT3 using IHC, mutational and RT-PCR analyses correlated with clinical data.
Results
In patients' samples, IHC analysis showed that in all but one repeated glioma resections from individual patients pSTAT3 levels were elevated. Higher pSTAT3 levels as well as MGMT methylation status corresponded with a shortened survival of these patients. Further analyses carried out in cryopreserved glioma samples revealed upregulation of STAT3 in an untreated patient corresponding with upregulation of hypoxia factors (HIF1α, HIF1β), proangiogenic factor VEGFA and EGFR. STAT3 knockout in glioma cells produced a similar trend - downregulation of hypoxia and proangiogenic factors.
Conclusions
Our results demonstrated a biological relationship between the expression of pSTAT3, hypoxia and proangiogenic factors and MGMT methylation in both cultivated glioma cells and glioma resected samples. Moreover, we discovered that pSTAT3 levels tend to increase in repeated resections. MGMT methylation status and increased pSTAT3 levels in these samples correlate with shorter survival of investiagted glioma bearing patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Ministry of Health, Czech Republic, project No. NU20-03-00360.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract